Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Myriad Genetics, Inc. (NASDAQ: MYGN) closed at $26.39 in the last session, up 0.42% from day before closing price of $26.28. In other words, the price has increased by $0.42 from its previous closing price. On the day, 0.57 million shares were traded. MYGN stock price reached its highest trading level at $26.55 during the session, while it also had its lowest trading level at $26.0.
Ratios:
We take a closer look at MYGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.96. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 28, 2024, initiated with a Overweight rating and assigned the stock a target price of $35.
On June 27, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $29.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 11 ’24 when DIAZ PAUL J sold 15,000 shares for $26.72 per share. The transaction valued at 400,800 led to the insider holds 977,378 shares of the business.
Muzzey Dale sold 2,100 shares of MYGN for $54,961 on Sep 11 ’24. The Chief Scientific Officer now owns 108,013 shares after completing the transaction at $26.17 per share. On Sep 11 ’24, another insider, Muzzey Dale, who serves as the Officer of the company, bought 2,100 shares for $26.17 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 2396750336 and an Enterprise Value of 2442749184. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.99 while its Price-to-Book (P/B) ratio in mrq is 3.24. Its current Enterprise Value per Revenue stands at 3.045 whereas that against EBITDA is -49.852.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $29.08, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is -2.55%, while the 200-Day Moving Average is calculated to be 15.78%.
Shares Statistics:
According to the various share statistics, MYGN traded on average about 790.99K shares per day over the past 3-months and 787200 shares per day over the past 10 days. A total of 89.90M shares are outstanding, with a floating share count of 87.18M. Insiders hold about 4.00% of the company’s shares, while institutions hold 101.97% stake in the company. Shares short for MYGN as of 1723680000 were 3876782 with a Short Ratio of 4.99, compared to 1721001600 on 3836708. Therefore, it implies a Short% of Shares Outstanding of 3876782 and a Short% of Float of 5.9799999999999995.
